Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 536

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 536
---
 2023 and 2022, the Company had $0.2 million due to the CEO of the Company for compensation under his employment agreement for both years.

<div align='center'>F-82</div>

TABLE OF CONTENTS

LIMINATUS PHARMA, LLC NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 2023 AND 2022 Viral Gene As of December 31, 2023 and 2022, the Company has $0.1 million due from Viral Gene included in due from related party in the balance sheets for a short-term loan to Viral Gene and expense paid on behalf of Viral Gene. The Company’s CEO is also the CEO of Viral Gene. The loan does not bear any interest and imputed interest would be immaterial. Note 5. Debt The Company has the following debt outstanding as of December 31, 2023 and 2022 (in thousands):

| ​                                
 ​                                | ​ 
 ​ | ​ 
 ​ | ​                                     
 ​                                     | ​ 
 ​ | ​ 
 ​ | December 31, 
 2023         |   |        |   | ​ | ​ | 2022 |   |        |   | ​ 
 ​ |
|:---------------------------------|:--|:--|:--------------------------------------|:--|:--|:-------------|:--|-------:|:--|:--|:--|:-----|:--|-------:|:--|:--|
| Feelux Bonds                     | ​ | ​ | Short-term debt, net, related parties | ​ | ​ | ​            | $ | 10,000 | ​ | ​ | ​ | ​    | $ | 10,000 | ​ | ​ |
| Car-Tcellkor Loan                | ​ | ​ | Short-term debt, net, related parties | ​ | ​ | ​            | ​ |    800 | ​ | ​ | ​ | ​    | ​ |    800 | ​ | ​ |
| Ewon Loan                        | ​ | ​ | Short-term debt, net, related parties | ​ | ​ | ​            | ​ |  2,000 | ​ | ​ | ​ | ​    | ​ |  5,000 | ​ | ​ |
| Valetudo Loan                    | ​ | ​ | Short-term debt, net, related parties | ​ | ​ | ​            | ​ |    700 | ​ | ​ | ​ |